報價延遲最少15分鐘:2026/06/21 10:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.96 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.65/--
|
|
企業價值
1.44B
|
| 資產負債 |
|
每股賬面淨值
-2.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
74.21M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others. |
